Have a feature idea you'd love to see implemented?
Let us know!
MNPR Monopar Therapeutics
Price (delayed)
$19.71
Market cap
$104.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$98.01M
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of
Highlights
The EPS has grown by 45% YoY and by 14% from the previous quarter
The net income has grown by 32% year-on-year and by 9% since the previous quarter
Monopar Therapeutics's quick ratio has increased by 25% YoY but it has decreased by 18% from the previous quarter
The equity has contracted by 25% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of MNPR
Market
Valuations
Earnings
Shares outstanding
5.28M
Market cap
$104.03M
Enterprise value
$98.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$6.47M
EBITDA
-$6.47M
Free cash flow
-$5.95M
Per share
Balance sheet
Liquidity
EPS
-$1.97
Free cash flow per share
-$1.69
Book value per share
$1.41
Revenue per share
$0
TBVPS
$1.72
Total assets
$6.07M
Total liabilities
$1.12M
Debt
$0
Equity
$4.95M
Working capital
$4.95M
Debt to equity
0
Current ratio
5.41
Quick ratio
5.36
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-87.8%
Return on equity
-107.5%
Return on invested capital
N/A
Return on capital employed
-130.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNPR stock price
How has the Monopar Therapeutics stock price performed over time
Intraday
3.74%
1 week
8.12%
1 month
275.43%
1 year
1,240.82%
YTD
1,059.41%
QTD
192.43%
Financial performance
How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7M
Net income
-$6.47M
Gross margin
N/A
Net margin
N/A
The net income has grown by 32% year-on-year and by 9% since the previous quarter
The operating income has grown by 29% YoY and by 7% from the previous quarter
Growth
What is Monopar Therapeutics's growth rate over time
Valuation
What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
14.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 45% YoY and by 14% from the previous quarter
The equity has contracted by 25% YoY and by 19% from the previous quarter
Efficiency
How efficient is Monopar Therapeutics business performance
MNPR's return on equity is up by 5% year-on-year and by 2.8% since the previous quarter
Dividends
What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNPR.
Financial health
How did Monopar Therapeutics financials performed over time
The total liabilities has declined by 43% year-on-year but it is up by 3.1% since the previous quarter
The total assets has declined by 29% year-on-year and by 15% since the previous quarter
The company's debt is 100% lower than its equity
The equity has contracted by 25% YoY and by 19% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.